Cognition Therapeutics, Inc. (CGTX) came out with a quarterly loss of $0.04 per share versus the Zac

Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.04) per share which beat the a

PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a cli

PURCHASE, N. Y. , July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a c

Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FD

Gainers Pulsenmore (NASDAQ:PLSM) shares moved upwards by 160.5% to $8.88 during Wednesday's reg

Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinic

- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Di

Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinic

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “C

PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a cli

- Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLO

The ongoing EAP has been extended to provide two years of treatment for participants, thanks to a ge

PURCHASE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Co

Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational pla

Cognition Therapeutics, Inc. (NASDAQ: CGTX - Get Free Report) CEO Lisa Ricciardi bought 9,175 shares

Cognition Therapeutics, Inc. (NASDAQ: CGTX - Get Free Report) CFO John Brendan Doyle acquired 10,000

Cognition Therapeutics (NASDAQ: CGTX) executives told investors at the Needham conference that the c

Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neu

PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a cl

Advancing Zervimesine (CT1812) towards late-stage trials for  dementia with Lewy bodies (DLB) psycho

Cognition Therapeutics (NASDAQ: CGTX) used its fourth-quarter and full-year 2025 earnings call to ou

Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript

Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.01) per share which beat the a

-Advancing zervimesine clinical development in DLB psychosis –  - Meeting with FDA Division of Psych

PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a cl

Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinic

Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clini

Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company dev

Cognition Therapeutics, Inc. (NASDAQ: CGTX), today announced that a manuscript entitled, "Phase

Common StockPreferred StockDebt SecuritiesWarrantsUnitsSubscription Rights​We may offer and sell up

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cognition Therapeutics (NASDAQ:CGTX

Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clini

Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company de

B. Riley Securities analyst William Woods reiterates Cognition Therapeutics (NASDAQ:CGTX) with a

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cognition Therapeutics (NASDAQ:CGTX

Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company dev

Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.06) per share which beat the a

https://www.sec.gov/Archives/edgar/data/1455365/000110465925089737/tm2525997d1_ex99-1.htm

- The offering was made to two new fundamental institutional investors -- The Company intends to use